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Abstract
Neuroblastic (N) type neuroblastoma (NB) is the
predominant cell type in NB tumors. Previously, we
determined that activated nuclear factor KB (NF-KB) is
required for doxorubicin and etoposide to kill N-typeNB
cells. This study was undertaken to determine how NF-
KB is activated by these agents. The results show that
p53 protein levels increase within 15 to 30 minutes of
treatment. This increase occurs before the degradation
of inhibitor of NF-KB (I-KB)A and theNF-KB–dependent
activation of gene transcription. Moreover, p53 is nec-
essary for NF-KB activation because cells with inactive
p53 were resistant to NF-KB–mediated cell death. This
pathway was further defined to show that p53 leads to
the activation of MAPK/ERK activity kinase (MEK) 1
through a process that depends on protein synthesis
and H-Ras. MEK1, in turn, mediates I-KB kinase ac-
tivation. Together, these results demonstrate for the
first time howNF-KB is activated in NB cells in response
to conventional drugs. Furthermore, these findings
provide an explanation as to why H-Ras expression
correlates with a favorable prognosis in NB and identify
intermediary signaling molecules that are targets for
discovering treatments for NB that is resistant to
conventional agents.
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Introduction
Neuroblastoma (NB), amalignancy of childhood, arises from
the neoplastic transformation of neural crest cells or cells
of neural crest origin. Despite intensive therapy with con-
ventional drugs, prognosis remains poor for advance-stage
cases and the chance of long-term survival is < 30% [1].
Understanding the pathogenesis of NB is complicated by
the heterogeneous nature of cell types within these tu-
mors. When NB cells are grown in vitro, distinct func-
tional phenotypes result, with the most prevalent cell types
being neuroblastic (N) type and schwannian/stromal (S) type.
N-type cells grow in culture as poorly attached aggregates of
small round cells, exhibit neurite-like processes, possess en-
zymatic activity required for neurotransmitter synthesis, are
MYCN-amplified, and are tumorigenic in mice [2–10]. In con-
trast, S-type cells grow with a flattened and adherent mor-
phology in culture, do not synthesize neurotransmitters, are
not MYCN-amplified but can express low levels of protein, and
are generally incapable of forming tumors when xenografted
into nude mice [2,3,9,10].
In recent studies, we have determined that the levels of
nuclear factor nB (NF-nB) basal activity and the consequences
of activating NF-nB also differ between S-type and N-type NB
cells. In S-type cells, NF-nB is constitutively active and is
required for survival [11]. In contrast, NF-nB is not constitutively
active in N-type cells, and when its activity is induced [e.g., by
treatment with doxorubicin (Dox)], it leads to cell death [12].
NF-nB proteins constitute a family of mammalian transcrip-
tion factors that bind a consensus DNA motif. There are five
identified members of this family: NF-nB1 (p50), NF-nB2 (p52),
RelA (p65), RelB, and c-Rel. At baseline, NF-nB associates
with one of several inhibitory inhibitor of NF-nB (I-nB) species,
which excludes NF-nB from the nucleus. I-nB kinase (IKK) a
and b protein serine kinases directly phosphorylate I-nB,
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triggering its ubiquitination and proteasomal degradation,
thereby releasing NF-nB, which then translocates to the
nucleus to regulate transcription [13].
Inmany cell types, NF-nBmediates resistance against cell
death by inducing gene expression that blocks apoptotic
signals. However, in some cell types, NF-nB triggers apop-
tosis. Although less frequently observed than prosurvival
functions, several examples of NF-nB–induced death have
been reported in neuronal cell types. For example, dopamine-
induced death of pheochromocytoma cells and neuronal
death in response to ischemia require NF-nB [14,15]. More-
over, we have previously demonstrated that, in N-type NB
cells, Dox induces I-nBa degradation and increases the DNA
binding of NF-nB p65/p50 heterodimers, and specific in-
hibition of NF-nB renders cells resistant to Dox [12].
Although the phosphorylation of I-nBa is the best-
characterized mechanism leading to NF-nB activation, other
mechanisms are also known. The 90-kDa ribosomal S6 ki-
nase (pp90/Rsk1) is a signal transactivator and is part of
mitogen-activated protein kinase (MAPK) cascade. pp90/
Rsk1 directly phosphorylates p65, leading to increased
NF-nB activity because phosphorylated p65 does not bind
its inhibitor, I-nBa [16]. Interestingly, pp90/Rsk1, as well as
otherMAPKs includingMAPK/ERKactivity kinase (MEK) 1/2,
directly phosphorylates the IKK complex and therefore has
the potential to regulate NF-nB at multiple levels.
p53, a tumor suppressor, inhibits cell growth and induces
apoptosis [17]. For example, fibroblasts derived from p53
knockout mice are resistant to a diverse group of anticancer
agents, including etoposide (VP16), 5-fluorouracil, and Dox
[18]. VP16-induced apoptosis of ovarian cancer cells re-
quires p53, and reintroduction of wild-type p53 into p53-null
tumor cells reestablishes chemosensitivity [19,20]. Given
that the N-type NB cells used to demonstrate drug-induced
NF-nB–mediated cell death contain wild-type p53, we hy-
pothesized a link between p53 and NF-nB activation. Indeed,
Ryan et al. [21] demonstrated that induction of wild-type p53
led to activation of NF-nB in Saos-2 osteosarcoma cells.
In this report, we demonstrate the functional importance
and interconnection of p53, H-Ras, MEK1, IKKa/b, and NF-
nB in chemotherapy-induced N-type cell death. The results
indicate that p53 is required for chemotherapy-induced NF-
nB activation and cell death. Dox and VP16 trigger cell death
throughaprocess that beginswith p53 response followedbya
p53-dependent sequential activation of MEK1 and IKKa/b,
which depends on intervening protein synthesis and H-Ras.
These findings are discussed with respect to the significance
of implicating H-Ras (a favorable prognostic marker) and
alternative therapeutic targets for chemoresistant NB.
Materials and Methods
Cell Lines
HumanNB cell lines SH-SY5Yand IMR32were cultured in
minimal essential medium (MEM) supplemented with 10%
(vol/vol) fetal bovine serum, 2 mM glutamine, 100 U/ml
penicillin, and 100 mg/ml streptomycin. The cells were main-
tained in a humidified 5% CO2 incubator at 37jC. The SH-
SY5Y cell line stably expressing c90p53 (c90p53/SH-SY5Y)
was generated as previously described [22] and maintained
in routine MEM with hygromycin (500 mg/ml) (Invitrogen,
Carlsbad, CA). SK-N-BE(2) cells were generously provided
by Dr. C. Patrick Reynolds (Children’s Hospital of Los
Angeles, Los Angeles, CA) and maintained in MEM.
Generation of SH-SY5Y Cells Stably Expressing E6
SH-SY5Y cells were transfected with an expression plas-
mid encoding E6 or vector control. Transfection was carried
out using LipofectAMINE PLUS (Invitrogen) according to the
manufacturer’s instructions. After 48 hours of transfection,
cells were cultured in a medium containing G418 (500 mg/ml)
(Gibco BRL, Grand Island, NY). Individual colonies were
propagated separately, and transfectants expressing high
levels of E6 were chosen for subsequent studies.
Cell Viability Assays
NB cells were plated at 1.2  104 cells/well in 96-well
culture plates. For experiments with dominant-negative (DN)
H-Ras, N17, cells were transfected and incubated overnight
with the vector. On the following day, the cells were tryp-
sinized and plated in 96-well plates. After being allowed to
attach overnight, the cells were treated in triplicate with Dox
or VP16 at indicated concentrations. On consecutive days,
the cells were incubated with tetrazolium salt [3-[4,5-di-
methylthiazol-2-yl]-2,5-diphenyltetrazolium bromide] (MTT;
1 mg/ml) at 37jC for 4 hours and then lysed in a buffer con-
taining 20% (wt/vol) sodium dodecyl sulfate (SDS) and 50%
(vol/vol) N,N-dimethylformamide (pH 4.5). Absorbance at
600 nM (A600) was determined using an ELX 808 automated
microplate reader (Bioteck Instruments, Winnoski, VT). After
the subtraction of background absorbance, the A600 of the
drug-treated cells was divided by that of untreated cells to
obtain the percentage of viable cells. Student’s paired t test
was used to test the significance of differences.
Determination of NF-jB–Dependent Reporter
Gene Activation
SH-SY5Yand IMR32 cells were transfected with 1 mg of the
reporter plasmid pBVIx-Luc, which contains six NF-nB recog-
nition sites within the promoter sequence linked to the lucifer-
ase reporter gene (gift from Gabriel Nun˜ez, University of
Michigan, Ann Arbor, MI). Briefly, the cells were grown in six-
well tissue culture plates up to 50% confluence. Twenty-four
hours later, the cells were transfected using a mixture of DNA
and LipofectAMINE PLUS in OPTI-MEM (Invitrogen). To en-
sure identical transfection efficiency in control and treated
cells, the cells were replated 24 hours after transfection into
12-well plates; after attachment, identical wells were treated
with Dox (0.5 g/ml), VP16 (10 g/ml), or vehicle control. Cell
extracts were harvested by lysis, and luciferase activity was
determined using the Luciferase Assay System (Promega,
Madison WI) according to the manufacturer’s instructions.
Light outputwasmeasuredwith aMonolight 2010 luminometer
(Analytical Luminescence Laboratory, Ann Arbor, MI). Lucifer-
ase activity was normalized to protein concentration.
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Measurement of NF-jB Activation by Electromobility
Shift Assay (EMSA)
Aliquots of nuclear extracts (10 mg of protein), prepared as
described [23] from SH-SY5Y cells following treatment, were
added to a reaction buffer containing 250 mM NaCl, 50 mM
Tris (pH 7.6), 5 mM dithiothreitol, and 1 mg/ml poly(dI–dC)
(Amersham Pharmacia Biotech, Buckinghamshire, UK). The
mixture was incubated with 5  104 cpm of a [a-32P]dATP–
labeled oligonucleotide probe containing an NF-nB bind-
ing site (5V-AGT TGA GGG GAC TTT CCC AGG C-3V). For
antibody supershift assays, 1 mg of monoclonal antibody
specific for either the p65 or the p50 subunit of NF-nB (Santa
Cruz Biotechnology, Santa Cruz, CA) was added with nu-
clear proteins, and reactions were incubated at 24jC for
20 minutes. Samples were resolved on 6% polyacrylamide
gels in Tris–glycine buffer. Gels were dried and subjected
to autoradiography.
Immunoblot Analysis
Cells were harvested and lysed in a buffer containing
50 mM Tris–HCl, 5 mM NaCl, 2% SDS (wt/vol), and 10%
glycerol (vol/vol). Protein was quantitated using the DC Pro-
tein Assay System (BioRad Laboratories, Hercules, CA).
Protein from whole-cell lysates (25–35 mg) was resolved by
SDS polyacrylamide gel electrophoresis on 10% to 15%SDS
polyacrylamide gels and transferred to Hybond-P PVDF
membranes (Amersham Pharmacia Biotech, Peapack, NJ)
by electroblotting. Primary antibodies used in this study
included the following: p53 (1:1000; CalBiochem, La Jolla,
CA); IKKa/b (1:200; Upstate Biotech, Lake Placid, NY);
I-nBa, MEK1, pMEK1, pIKKa, p44/42 MAP kinase (ERK)
1/2, and pERK1/2 (1:500; Cell Signaling, Beverly, MA); and
b-tubulin (1:2000; Sigma, St. Louis, MO). Antigen–antibody
complexes were detected using enhanced chemilumines-
cence technique (ECL Detection Kit; Amersham Inter-
national) followed by exposure of membranes to Kodak
XAR film (Eastman Kodak Co., Rochester, NY).
MEK1/Rsk1 Kinase Assays
MEK1 and Rsk1 kinase activities were determined in NB
cells following Dox or VP16 treatment. Briefly, cells were
transiently transfected with pCMV5-MEK1 or pcDNA3-
HA-Rsk1 using LipofectAMINE PLUS. Whole-cell lysates
(100 mg) were incubated overnight at 4jC with anti-MEK1
antibody (Santa Cruz Biotechnology) to immunoprecipitate
MEK1 or with anti-HA antibody (Santa Cruz Biotechnology)
to immunoprecipitate Rsk1. Kinase assays were performed
using a MEK1 kinase assay kit or an S6 kinase assay kit
(UpstateBiotech) according to themanufacturer’s instructions.
Inhibition of Protein Synthesis with Cyclohexamide
SH-SY5Y cells were plated as described above. Cells
were pretreated for 1 hour with cyclohexamide (CHX; 2 mg/
ml) or vehicle control (0.01% DMSO) followed by treatment
with Dox (0.5 mg/ml). Cells were incubated for 4 hours, after
which cell lysates were collected. Phospho-MEK1 and p21
protein levels were detected by immunoblot analysis, as
described above.
Pharmacological Inhibition of the NF-jB Pathway
SH-SY5Y cells were treated with the MEK1/2 inhibitor
PD98059 (CalBiochem), the IKK inhibitor BAY 11-7082 (Cal-
Biochem), or the H-Ras geranyl–geranyl transferase inhibi-
tor GGTI-287 (CalBiochem). For immunoblot analysis, cells
were pretreated with the appropriate inhibitor for 2 hours
before the addition of Dox or VP16. Proteins were isolated
as described above. For reporter analysis, SH-SY5Y cells
were transfected with the NF-nB reporter vector as described
above. On the next day, cells were incubated with GGTI-287
or vehicle control in MEM for 24 hours at indicated concen-
trations before the addition of Dox. After incubation, lucifer-
ase activity was measured as described above.
Modulation of H-Ras through Mutant Forms
SH-SY5Y,E6/SH-SY5Y, andSK-N-BE(2) cells were trans-
fected, as described above, with an expression vector for a
constitutively active form of H-Ras, V12, or DN mutant N17.
For experiments with V12 H-Ras, cells were incubated over-
night with the vector cotransfected with the NF-nB luciferase
reporter vector. On the next morning, cell lysates were
harvested, and luciferase activity was measured as de-
scribed above. For experiments with DN N17 H-Ras, cells
were cotransfected with the NF-nB luciferase reporter vector.
On the next day, cells were treated with vehicle or Dox
(0.5 mg/ml) for 8 hours. Cell lysates were collected, and lu-
ciferase activity was measured.
Quantitation of mRNA Levels by Real-Time Polymerase
Chain Reaction (PCR)
Cells were treated with Dox as indicated, then total
RNA was isolated with the RNeasy kit (Qiagen, Valencia,
CA) according to the manufacturer’s directions. RNA was
reverse-transcribed to cDNAusing oligo-dTas primer (Super-
scriptase II; Invitrogen). Message levels were quantitated by
real-time PCR using gene-specific primers (Applied Bio-
systems, Foster City, CA) on the Applied Biosystems 7300
Real-Time PCR System.
Results
VP16, Like Dox, Induces NF-jB Activation
Previously, we have determined that NF-nB transcriptional
activity was induced by Dox in NB cells [12]. Because VP16 is
able to activate NF-nB in other cell types [24], we postulated
that its mechanism in NB is similar to that of Dox. To test
this, NF-nB sequence-specific DNA binding was measured
following treatment with VP16 (10 mg/ml; 2 hours) or Dox
(0.5 mg/ml; 8 hours). Nuclear extracts prepared from treated
SH-SY5Y cells were incubated with 32P end-labeled double-
strandedDNA containing a consensus NF-nB recognition site,
and binding was detected by EMSA. As shown in Figure 1A,
untreatedN-type cells have no detectableNF-nBDNA-binding
activity. Following treatment with Dox or VP16, NF-nB DNA
binding is detected as a specific band that, on supershift, is
shown to be composed of p65/p50 heterodimers.
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To test NF-nB transcriptional activation after VP16 treat-
ment, wemeasuredNF-nB–dependent gene transcription by
transiently transfecting SH-SY5Y and IMR32 cells with a
reporter plasmid containing six NF-nB consensus-binding
sites tandemly placed within the luciferase promoter [25].
Both Dox and VP16 activated NF-nB transcriptional activity
within 8 hours (Figure 1B). These findings suggest that, like
Dox, VP16 induces NF-nB heterodimer activation and spe-
cific NF-nB transcriptional response.
To determine if endogenous NF-nB–responsive genes
are regulated by drug treatment, mRNA levels corresponding
to selected genes with (I-jBa, RelB, and Bax) or without
(GAPDH ) NF-nB consensus elements in their promoters
were measured. RNA isolated from SH-SY5Y cells treated
with Dox for 6 hours was analyzed by real-time PCR. As
shown in Figure 1C, the levels of transcripts for I-nBa and
RelB increased in response to Dox. Furthermore, the pro-
apoptotic gene Bax was also upregulated in response to
Dox. Transcript levels of the non–NF-nB–responsive gene
GAPDH were unchanged. Thus, this experiment demon-
strates regulation of transcripts from endogenous NF-nB–
responsive genes, further supporting the hypothesis that
NF-nB is activated in response to Dox.
IKK Kinase Complex Mediates Dox and VP16-Induced
NF-jB Activation
Activation of NF-nB p65/p50 heterodimers typically
involves phosphorylation of I-nB at specific serine residues
[13]. In Saos-2 cells, NF-nB mediates p53-controlled
programmed cell death through a process in which mitogen-
activated ribosomal pp90/Rsk1 (S6 kinase) phosphorylates
I-nB. To determine the involvement of pp90/Rsk1 in response
to Dox and VP16, SH-SY5Y and IMR32 cells were treated
with Dox or VP16, and lysates were immunoblotted to detect
the active phosphorylated formof pp90/Rsk1. Phosphorylation
of pp90/Rsk1 increased within 2 to 4 hours after exposure to
these agents (data not shown). Next, we cotransfected
pcDNA3-Rsk1-D205N, encoding a DN form of pp90/Rsk1,
with a mutated ATP-binding site in the amino-terminal kinase
domain, together with the NF-nB transcription reporter
plasmid. High-level expression of DN mutant was confirmed
by immunoblotting (data not shown). Surprisingly, neither Dox-
induced nor VP16-induced NF-nB activation was reduced in
cells expressing DN pp90/Rsk1 compared to vector-only
control cells (Figure 2A). To ensure that the expression of
DN pp90/Rsk1 was sufficient to block wild-type activity, trans-
fected cells were exposed to phorbol 12-myristate 13-acetate
(PMA) for 2 hours to induce NF-nB by directly activating pp90/
Rsk1, which is essential for NF-nB activation by PMA [26]. As
seen in Figure 2A, the expression of DN pp90/Rsk1 effectively
blocked PMA-induced NF-nB activity. Collectively, these
results suggest that pp90/Rsk1 is not necessary for NF-nB
activation by Dox or VP16 in NB cells.
Because our previous studies demonstrated that I-nBa
levels decrease as part of drug-induced NF-nB activation, we
hypothesized that IKK mediates this response by phosphor-
ylating I-nBa. Direct evidence of IKK activation by Dox was
detected by immunoblotting with antibodies specific for
phospho-IKKa, which showed that the phosphorylated (ac-
tive) form of IKK was induced within 1 hour of exposure to
drugs (Figure 2B). We also tested IKK’s involvement by
transfecting cells with DN mutant forms of IKKa and IKKb.
SH-SY5Yand IMR32 cells were cotransfected with pcDNA3-
DN-IKKa-Flag, pcDNA3-DN-IKKb-Flag, or control plasmid,
Figure 1. Dox and VP16 induce NF-jB activation. (A) Nuclear extracts
prepared from SH-SY5Y cells treated with Dox (0.5 g/ml; 2 hours) or VP16
(10 g/ml; 8 hours) were used in EMSA and supershift assays. Supershift
using anti-p65 or anti-p50 antibodies confirms that NF-jB heterodimers are
present. (B) SH-SY5Y and IMR32 cells transfected with the luciferase reporter
plasmid pBVIx-Luc were treated with Dox (0.5 g/ml) or VP16 (10 g/ml) for
8 hours. Luciferase activity (normalized to protein concentration) is reported
as fold induction over untreated controls (mean ± SD) based on three ex-
periments. (C) SH-SY5Y cells were treated with Dox (0.5 g/ml; 6 hours), and
total RNA was isolated. mRNA was reverse-transcribed, and the resulting
cDNA was subjected to real-time quantitative PCR using gene-specific
primers. Data are reported as relative expression (compared to GAPDH in
untreated cells). *P < .05 (n = 6).
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along with the NF-nB reporter plasmid. As seen in Figure 2C,
expression of DN-IKKa or DN-IKKb blocked drug-induced
NF-nB activation, arguing that IKK activity is necessary.
These results indicate that IKK is activated and necessary
for Dox-induced and VP16-induced activation of NF-nB.
Finally, the presence of IKK activation was verified by mea-
suring I-nB levels. As shown in Figure 2D, treating SH-SY5Y
cells with Dox or VP16 results in lower levels of I-nB protein.
These results are consistent with Dox and VP16 inducing
IKK activation that leads to I-nB degradation and subsequent
NF-nB activation.
MEK Mediates Dox and VP16-Induced NF-jB Activation
Because MEK1/2 is associated with NF-nB activation, we
next tested whether Dox and VP16 activate MEK1/2, leading
to NF-nB response. Consistent with this hypothesis, phos-
phorylated (active) MEK1/2 was detected in cells following
Dox or VP16 treatment (Figure 3A). Phosphorylated MEK1/2
is induced within 15 minutes of Dox or VP16 treatment. To
directly confirm MEK activity, we measured MEK1 kinase
function in lysates prepared from SH-SY5Y cells treated with
Dox or VP16. Based on the phosphorylation of recombinant
ERK2 as a substrate in in vitro kinase assays, MEK1 activity
increased in response to both Dox and VP16 (Figure 3B).
In subsequent experiments, we evaluated whether MEK1/
2 activity is necessary for drug-induced NF-nB activation
using the MEK1/2–selective kinase inhibitor PD98059. As
shown in Figure 3C, PD98059 dose-dependently inhibited
Dox-induced NF-nB activation as assessed by NF-nB–
dependent luciferase reporter gene expression. Because
PD98059 was noted to have significant cytotoxic effects on
NB cells after longer periods of incubation, its ability to block
Dox-induced cell death was not determined. Together, these
results support the hypothesis that MEK1/2 is activated as
part of response to Dox and VP16 and argue that its activity
is necessary for NF-nB activation, which is itself necessary
for drug-induced killing.
MEK Activates NF-jB through IKK
Next, we examined the relationship between MEK and
IKK, testing the hypothesis that MEK activation is indepen-
dent (and therefore upstream) of IKK. SH-SY5Y cells were
pretreated with the MEK inhibitor PD98059 before exposure
to Dox. As expected, pretreatment with PD98059 blocked
I-nBa degradation, in addition to inhibiting ERK phosphory-
lation in Dox-treated and VP16-treated cells (Figure 4). This
result indicates that IKK is activated downstream of MEK
and confirms that IKK is required for I-nBa degradation in
response to Dox treatment.
p53 Mediates NF-jB–Dependent Death
Dox and VP16 cause DNA damage, and both agents have
previously been shown to induce p53 expression in carci-
noma cells. In fact, Dox treatment of SH-SY5Y cells results in
rapid and sustained upregulation of p53 [27]. Because work
by Ryan et al. [21] suggested that wild-type p53 is important
for drug-induced NF-nB activity and that these NB cell lines
express wild-type p53, we tested whether cell death, NF-nB
activation, andMEK activation are p53-dependent responses
to Dox and VP16 in N-type cells.
p53 levels were assessed by immunoblotting lysates of
SH-SY5Y cells after treatment with Dox or VP16. As shown in
Figure 2. IKK, but not pp90/Rsk1, is required for NF-jB activation in response to Dox and VP16. (A) SH-SY5Y cells were cotransfected with pcDNA3-DNRsk1 and
pBVIx-Luc reporter plasmid. Twenty-four hours after transfection, cells were treated with Dox (0.5 g/ml; 8 hours), VP16 (10 g/ml; 6 hours), or PMA (20 ng/ml;
2 hours). Luciferase activity was determined in three separate samples. Results show induction relative to untreated control cells and are presented as mean ± SD.
(B) SH-SY5Y cells were treated with Dox (0.5 g/ml) for indicated times. Whole-cell lysates were immunoblotted to detect total and phosphorylated IKK. (C) SH-
SY5Y and IMR32 cells were cotransfected with pcDNA3-DNIKKa-Flag or pcDNA3-DNIKK-Flag and pBVIx-Luc reporter plasmid. Twenty-four hours after
transfection, cells were treated with Dox (0.5 g/ml) for 8 hours. Luciferase activity (fold induction relative to untreated cells) is shown as the mean ± SD of three
experiments. (D) SH-SY5Y cells were treated with Dox (0.5 g/ml) or VP16 (10 g/ml) for indicated times. Cell lysates (30 g) were immunoblotted to detect I-jBa.
The same blots were probed for -tubulin to confirm equivalent loading (not shown).
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Figure 5A, p53 protein increases within 10 minutes of VP16
treatment and within 60 minutes of Dox treatment. Moreover,
when lysates are immunoblotted to detect I-nBa, the in-
crease in p53 was observed to precede the decrease in
I-nBa (Figure 2D). This temporal order is consistent with
the hypothesis that p53 mediates NF-nB signaling.
Next, to assess the functional contribution of p53 to NF-nB
response, SH-SY5Y cells were stably transfected to express
the E6 protein derived from human papilloma virus type 16.
This viral protein binds to p53 and forces its degradation
[28]. The increase of p53 in response to drug treatment was
prevented in E6-expressing SH-SY5Y cells (Figure 5B).
Consistent with the hypothesis that killing by these drugs de-
pends on p53, E6/SH-SY5Y cells were less sensitive to both
Dox and VP16 killing than were vector controls (Figure 5B).
Using these same cells, we tested whether drug-induced ac-
tivation of NF-nB was also blocked as a consequence of re-
ducing p53 levels. As expected, when E6/SH-SY5Y cells
were transiently transfected with the NF-nB luciferase re-
porter plasmid, Dox-induced and VP16-induced luciferase
expression was suppressed, whereas expected induction
was observed in control cells (Figure 5C). Given the possi-
bility that E6 viral protein was acting through a non–p53-
specific mechanism, SH-SY5Y cells were transfected to
stably express DN mutant p53, which encodes the carboxy-
terminal portion (codons 302–393) of human p53 and forms
nonfunctional hetero-oligomers with endogenous wild-type
p53. This truncated form of p53 specifically interferes with its
transcriptional activity [22]. In cotransfection experiments, we
found that DN p53/SH-SY5Y cells also failed to increase
NF-nB–dependent luciferase activity in response to Dox
(data not shown) and, like E6-expressing cells, were less
sensitive to Dox killing. Dox (1 mM) killed 89.1% (± 0.15%) of
vector control but only 57.7% (± 0.8%) of DN p53–transfected
SH-SY5Y cells (P < .001). Together, these results provide
firm evidence that Dox-induced and VP16-induced NF-nB ac-
tivation and cell death are p53-dependent.
Because p53 andMEK1/2 are both necessary for NF-nB–
mediated death, experiments were conducted to determine
the interrelationship of MEK1/2 activation and p53 response.
First, phosphorylated ERK, a marker of MEK1/2 activity, was
measured in p53-depleted E6/SH-SY5Y cells following Dox
or VP16 treatment (Figure 6A). The results of this experiment
showed that reducing p53 attenuated ERK phosphorylation,
arguing that MEK1/2 activation is p53-dependent. Then, to
further verify that MEK1/2 acts downstream of p53, SH-SY5Y
cells were pretreated with PD90589 to inhibit MEK1/2 and
then immunoblotted to detect the level of p53 expression
following Dox and VP16 treatment. As shown in Figure 6B,
although PD98059 completely blocked ERK phosphorylation
Figure 3.MEK1 is activated byDox andVP16, andmediatesNF-jBactivation.
(A) SH-SY5Y cells were treated with Dox (0.5 g/ml) or VP16 (10 g/ml) for
indicated times. Cell lysates (30 g) were immunoblotted to detect MEK1
and pMEK1. (B) SH-SY5Y cells, transfected with pCMV-MEK1, were treated
with Dox (0.5 g/ml) or VP16 (10 g/ml). Kinase assays were performed on
immunoprecipitated MEK using exogenous ERK2 as substrate. Phospho-
ERK2 substrate was detected by immunoblotting. (C) SH-SY5Y cells tran-
siently transfected with the pBVIx-Luc reporter plasmid were treated with
Dox (0.5 g/ml) for 4 or 8 hours in the presence or in the absence of PD98059
(5, 10, and 50 M). Luciferase activity (fold induction relative to untreated
cells) is presented as the mean ± SD from three separate experiments.
Figure 4. MEK is required for I-jB degradation. SH-SY5Y cells were treated
withDox (0.5 g/ml) (A) or VP16 (10g/ml) (B) in the presence or in the absence
of PD98059 (20 nM). Cell lysates (35 g) were immunoblotted to detect endog-
enous pERK1/2, ERK1/2, and I-jBa. -Tubulin is shown as loading control.
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as expected (top panel ), it did not affect the drug-induced
increase in p53 (middle panel ). From these experiments, we
conclude that p53 induction is upstream of MEK activation
and that p53 is necessary for subsequent signaling lead-
ing to NF-nB activation–associated cell death, including
MEK activity.
Figure 5. E6/SH-SY5Y cells do not activate NF-jB and are resistant to Dox-induced and VP16-induced cell death. (A) SH-SY5Y cells were treated with Dox
(0.5 g/ml) or VP16 (10 g/ml) for indicated times, and p53 and -tubulin protein levels were determined by immunoblotting. (B) The viability of E6/SH-SY5Y and
vector control cells 24 hours following treatment with Dox or VP16 at indicated concentrations was determined by MTT. Data are presented as the mean ± SD from
three separate experiments. Insert shows that p53 levels are reduced in E6/SH-SY5Y cells. (C) E6/SH-SY5Y and vector control cells were transfected with the
pBVIx-Luc reporter plasmid; 24 hours later, cells were treated with Dox (0.5 g/ml; 4 hours) or VP16 (10 g/ml; 8 hours). Luciferase activity (fold induction relative
to untreated cells) is presented as the mean ± SD from three separate experiments.
Figure 6. p53 is an upstream mediator of Dox-induced and VP16-induced MEK activation. (A) E6/SH-SY5Y and vector control cells were treated with Dox (0.5 g/
ml) or VP16 (10 g/ml) for indicated times. Immunoblotting was performed to detect total and phosphorylated ERK1/2. -Tubulin is shown as loading control. (B)
Following pretreatment with PD98059 (20 nM; 1 hour), SH-SY5Y cells were treated with Dox (0.5 g/ml; 8 hours) or VP16 (10 g/ml; 6 hours), after which lysates
were immunoblotted to detect phosphorylated ERK and total p53. -Tubulin is shown as loading control.
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We also tested this apoptotic pathway in cells with ab-
normal p53 expression. SK-N-BE(2) NB cells contain only a
single nonfunctional p53 allele with a point mutation that
renders the protein transcriptionally inactive [29]. The con-
centration of Dox required to kill 50% of SK-N-BE(2) cells
exceeded 2 mg/ml, which is more than eight times that
required for the other N-type lines with wild-type p53 studied
here. Consistent with our proposedmodel, when SK-N-BE(2)
NB cells were exposed to either Dox or VP16, there was no
increase in NF-nB–dependent luciferase reporter gene ex-
pression and there was no evidence of MEK1/2 activation (no
phosphorylation of either MEK1 or ERK; Figure 7). These
results indicate that wild-type p53 transcriptional activity is
required for the activation of NF-nB–induced cell death.
H-Ras Mediates p53-Induced NF-jB Activation
We next explored the mechanism that links p53 activation
to MEK1 activation. Because the DN p53 mutant employed
above specifically interferes with p53 transcriptional activa-
tion, we hypothesized that p53-induced changes in gene
expression were involved. To test this, CHX was used to
block protein synthesis during Dox treatment. CHX blocked
the Dox-induced increase of p21 (an established p53-
responsive gene), the phosphorylation of MEK1, and the in-
crease in the level of p53 in response to Dox treatment (data
not shown). Thus, new protein synthesis is required for MEK1
activation. The results, however, do not exclude the pos-
sibility that other transcriptional events upstream of p53 may
also be necessary. Taken together with the data above
showing that transcriptionally inactive p53 mutants fail to
engage MEK1 activation, our results point to p53-dependent
change in gene expression mediating MEK1 activation.
In other systems, p53-induced gene expression has been
linked to MAPK cascade activation through the induced ex-
pression of G-protein–coupled receptors such as heparin-
binding growth factor– like growth factor receptor and DDR1
[30,31]. Moreover, G proteins such as H-Ras and K-Ras are
linked to MAPK activity and NF-nB activation [32–34]. Inter-
estingly, H-Ras expression is correlated with favorable out-
comes in NB, suggesting that this protein may facilitate
therapy-induced remission in NB [35]. Therefore, we decided
to test whether H-Ras mediates response to Dox by spe-
cifically coupling p53 to MAPK activity.
SH-SY5Y cells were treated with the geranyl–gernayl
transferase inhibitor GGTI-287, which blocks Ras prenylation
and inhibits its membrane targeting and activity [36]. As seen
in Figure 8A, GGTI-287 blocked Dox-induced NF-nB activa-
tion. Next, to confirm the involvement of Ras, we expressed a
DN mutant form of H-Ras and tested whether Dox-induced
NF-nB activation and cell death were affected. We found
that expression of DN H-Ras blocked Dox-induced NF-nB
Figure 7. MEK1 and NF-jB activation is suppressed in chemoresistant
mutant p53-expressing cells. (A) SK-N-BE(2) cells were transfected with the
pBVIx-Luc reporter plasmid and treated with Dox (0.5 g/ml; 8 hours) or VP16
(10 g/ml; 8 hours). Luciferase activity (normalized to total protein) is pre-
sented as arbitrary light units (mean ± SD) from three separate experiments.
(B) Lysates from SK-N-BE(2) cells, treated with Dox (0.5 g/ml) or VP16
(10 g/ml) for indicated times, were immunoblotted to detect total and
phosphorylated MEK1 and ERK1/2.
Figure 8. H-Ras is necessary for NF-jB activation in response to Dox. (A)
After transfection of the pBVIx-Luc reporter vector, SH-SY5Y cells were
treated with Dox (0.5 g/ml) for 8 hours in the absence or in the presence of
the geranyl –geranyl transferase inhibitor GGTI-287 at indicated concen-
trations. Luciferase activity (normalized to protein concentration) is shown as
fold induction over untreated cells (mean ± SD) based on three experiments.
(B) SH-SY5Y cells were cotransfected with DN H-Ras N17 or with an empty
vector along with the pBVIx-Luc reporter vector. After 24 hours, cells were
incubated in Dox (0.5 g/ml) for 8 hours. Luciferase activity (normalized to
protein) is shown as fold induction over untreated controls (mean ± SD)
based on four experiments.
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activation (Figure 8B). Moreover, when the Dox-induced
death of transfected cells was quantified, we found that, after
24 hours, 0.5 mM Dox killed 65% (± 10%) of vector control–
transfected SH-SY5Y cells but only 25% (± 16%) of DN
H-Ras–transfected SH-SY5Y cells (P < .01).
Finally, we explored conditions under which H-Ras acti-
vation may be sufficient to signal NB cell death. Cells were
transiently transfected to express the constitutively active
H-Ras mutant V12. As seen in Figure 9A, NF-nB activity
was induced in SH-SY5Y cells by V12 H-Ras. Moreover, in
E6/SH-SY5Y and SK-N-BE(2) cells, which each lacks p53,
NF-nB was activated in response to constitutively active
H-Ras (Figure 9, B and C). These results indicate that, in this
mechanism, H-Ras acts downstream of p53 and that it is
sufficient for activating NF-nB. As predicted, I-nB SR expres-
sion, which blocks NF-nB, abrogates V12 H-Ras effect on
NF-nB activation (Figure 9D).
Discussion
p53 is paramount in determining responsiveness to many
chemotherapeutic agents. Mutations in p53 or other disrup-
tions of the p53 pathway producemultidrug resistance in vitro
and in vivo [22]. Although p53 mutations occur in < 3% of
primary NB tumors, p53 mutation or loss of p53 function
commonly develops during therapy in association with drug
resistance [29,37,38]. Moreover, amplification of the p53
inhibitor MDM2, as well as homozygous deletion of the
p53-responsive gene CDKN2A (p16INK4a/p14ARF), has
been observed in NB cell lines and tumors [39,40]. Together,
these observations tie abnormal p53 responsiveness to the
tumorigenic behavior of NB, particularly with respect to
treatment resistance and relapse. Here, we provide evidence
that p53 is important in NB chemoresponsiveness as a criti-
cal mediator of chemotherapy-induced NF-nB activation—
a signal that can independently induce apoptosis in N-type
NB cells. Dox and VP16 are drugs that kill NB cells through an
NF-nB–driven response, and each increases p53 protein
levels. Using three independent strategies, our results show
that p53 is required for both of these drugs to activate NF-nB
and to kill N-typeNB cells. As shown in Figure 10, we outline a
pathway in which p53 activation leads to H-Ras–dependent
MAP kinase activity, resulting in NF-nB activation through the
IKK phosphorylation of I-nBa.
Our results implicate MEK1 downstream of p53. Ryan
et al. [21] have also shown that MEK1 is required for p53-
induced apoptosis in Saos-2 cells. No direct interaction
between p53 and MEK1 is known; therefore, it is likely that
intervening signaling is required. In untreated NB cells, p53 is
sequestered in the cytoplasm. In this regard, unpublished
data from our group show that Dox and VP16 cause not only
p53 accumulation but also nuclear translocation. Second,
our results with SK-N-BE(2) cells, which express p53 with
Figure 9. H-Ras acts downstream of p53 and upstream of NF-jB. SH-SY5Y (A), E6/SH-SY5Y (B), and SK-N-BE(2) (C) cells were cotransfected with a vector
expressing a constitutively active V12 H-Ras at the quantities shown and with the pBVIx-Luc reporter vector. Cells were incubated for 24 hours, after which cell
extracts were harvested. Luciferase activity (normalized for protein) was measured and is expressed in arbitrary light units (mean ± SD) based on three
experiments. (D) SRIjBaM/SH-SY5Y cells, which stably express the DN mutant form of I-jB that is resistant to modification by IKK, and vector controls were
transfected with V12 H-Ras or with an empty vector along with the pBVIx-Luc reporter vector. After 24 hours of incubation, cell lysates were isolated. Luciferase
activity (normalized to protein) is expressed in arbitrary light units (mean ± SD) based on three experiments.
Figure 10. Dox and VP16 signaling pathway in NB.
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a point mutation that completely abolishes transcriptional
activity, and our experiments with CHX suggest a require-
ment for p53-mediated gene transcription for MEK activation
in this model.
MAPKs consist of three families: ERK, c-Jun NH2-terminal
kinases, and p38-MAPKs. Only ERK1 and ERK2 are acti-
vated byMEK1. Following activation, ERK translocates to the
nucleus and phosphorylates a variety of substrates, includ-
ing pp90/Rsk1; the cytosolic phospholipase A2; transcription
factors c-Myc, Elk-1, NF-IL-6/C/EBP/NF-M, Tal-1, and Ets-2;
and STAT proteins [41]. Our results show that ERK1 is
present in NB cells and that it is phosphorylated in response
to Dox and VP16. Although ERK signaling pathways are
usually linked to cell survival, ERK1/2 can also be involved
in cell death [42–47]. Interestingly, ERK activation has pre-
viously been shown to mediate cell cycle arrest and apop-
tosis after VP16 or Dox treatment, independently of p53 [48].
A requirement for ERK in NF-nB signaling has also been
described in other cell lines. In T cells, macrophages, and
melanoma cells, ERK is necessary for NF-nB responses
induced by HIV-mediated CD4 stimulation, induced by lipo-
polysaccharide, or in constitutive baseline activity, respec-
tively [49–51]. Experiments are necessary to next test
whether ERK transduces the signal between MEK and IKK
in NB cells.
Small GTPases of the Ras family are important signaling
molecules in the regulation of a variety of cellular processes,
including growth, differentiation, and survival [52]. Growth
factors and other external stimuli lead to transient activa-
tion of Ras; however, mutations in Ras alleles, which occur in
30% of human tumors, result in a constitutively active protein
[53]. Active GTP-bound Ras signals to a variety of down-
stream effector pathways. The three most extensively char-
acterized Ras effectors are Raf kinase, phosphatidylinositol
3-kinase, and RalGDS [54]. The activation of Ras and its
downstream signal transduction cascades ultimately leads to
the activation of transcription factors involved in proliferation,
differentiation, and apoptosis [55]. Although normally thought
of as an oncogenic protein, our results indicate that H-Ras
mediates apoptosis in response to chemotherapy agents.
We showed that H-Ras is both necessary and sufficient to
activate NF-nB and to induce apoptosis in N-type NB cells. It
is tempting to speculate that its proapoptotic activity in NB
explains the direct correlation between H-Ras expression
and favorable outcomes in patients with NB [56]. It is intrigu-
ing that H-Ras, NF-nB, MEK, and ERK are each generally
understood to promote tumor growth but to possess death-
inducing roles in NB. These results support the need to define
the function of these signaling proteins according to disease
and cell type before applying therapeutic strategies that
target these proteins.
With respect to NB, our data suggest the potential to
circumvent p53-associated resistance by engaging H-Ras,
MEK1, IKK, and, potentially, even ERK. Genotoxic agents,
such as Dox and VP16, produce multiple effects in cells, in
addition to p53 stabilization and NF-nB activation. Many of
these effects, such as DNA adduct formation, oxygen radical
formation, and mitochondrial failure, are catastrophic, espe-
cially to normal cells. Therefore, therapeutic measures that
selectively activate appropriate downstream signal trans-
ducers may be effective against this disease independent
of p53 status and may be potentially less toxic. Conversely,
our results point to the potential risk of potent MAPK or IKK
inhibitors, which currently exist as experimental therapeutics,
to reduce the response of NB tumors to conventional agents
such as Dox or VP16.
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